Naturalistic psychedelic use and changes in depressive symptoms
Abstract While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the effects of psychedelic use
Abstract While growing evidence suggests that psychedelic-assisted therapy may have antidepressant effects in certain populations, little is known about the effects of psychedelic use
Abstract Objective Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader health behaviors remains
Abstract Psychedelic clinical study environments are frequently visually manipulated, such as art; however, there has been little study of how the art selected for display
Rationale Psychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models
Abstract Increasing evidence suggests that psychedelic experiences, undergone in controlled conditions, can have various durable psychological benefits. One such benefit is reductions in fear of
Abstract This commentary addresses the potential for a nocebo effect arising from the public discourse on psychedelics, especially considering the increasing interest and engagement with
Abstract A number of organizations have developed or are developing psychedelic integration groups, held in person or online. In parallel, there have been calls to
Abstract Hallucinogenic drugs are used because they have effects on the central nervous system. Their hallucinogenic effects probably occur via stimulation of serotonin receptors, namely,
Objective Can machine learning (ML) enable data‐driven discovery of how changes in sentiment correlate with different psychoactive experiences? We investigate by training models directly on
Purpose/Background There has been resurgence of interest in the therapeutic use of serotonergic (“classic”) psychedelics in major depressive disorder (MDD) and end-of-life distress. This commentary